✦ LIBER ✦

P-622 The in-vitro activity of erlotinib (TarcevaTM), a HER1/EGFR-TK inhibitor, and molecular correlates of response in non-small cell lung carcinomas

✍ Scribed by Eberhard, David A.; Fedorowicz, Grazyna; Williams, P. Mickey; Wu, Thomas; Ostland, Michael; Goddard, Audrey; Kerfoot, Christopher A.; Thompson, James; Pavich, Deborah; Ramsinghani, Sunjay S.

Book ID: 118572317
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 174 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92589-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-112 A phase I/II study of the anti-VEG

O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer

✍ Sandler, Alan B.; Mininberg, Eric; Henderson, Ted; Kim, Edward; Hong, Waun Ki; M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 182 KB